Claims for Patent: 8,821,872

Summary for Patent: 8,821,872

Title:	Identification and characterization of a specific CCK-C receptor antibody for human pancreatic cancer and its use for early detection and staging of pancreatic cancer
Abstract:	Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.
Inventor(s):	Smith; Jill P. (Camp Hill, PA), Matters; Gail L. (Hummelstown, PA), Christensen; Neil D. (Harrisburg, PA), Harms; John F. (Mechanicsburg, PA)
Assignee:
Application Number:	12/772,758
Patent Claims:	1. The 3B9.1 monoclonal antibody to the CCK-C receptor which receptor is a splice variant receptor of the CCK-B receptor that retains the 4th intron (also called CCK2Ri4sv). 2. A method employing the monoclonal antibody of claim 1 for detecting gastrointestinal or other tumors which possess the CCK-C receptor comprising the following steps: a) obtaining a biological sample believed to arise from a gastrointestinal or other tumor; b) contacting the biological sample with the monoclonal antibody to the CCK-C receptor; and c) using an appropriate assay detecting the binding of the antibody to a CCK-C receptor in the biological sample wherein binding of the antibody indicates the presence of the cancerous material. 3. The method of claim 2 in which an appropriate assay used in identifying the receptor in tissues or cells is flow cytometry, immunohistochemistry, protein analysis (western blots), PET or other forms of imaging scanning 4. The method of claim 2 in which the antibody may be combined with other agents or administered by nanotechnology including nanoparticles and nanoliposomes or other vehicle carrier devises to improve the target specific binding for diagnosis.

Details for Patent 8,821,872

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26